CN111788182B - 毒蕈碱性乙酰胆碱受体m4的拮抗剂 - Google Patents
毒蕈碱性乙酰胆碱受体m4的拮抗剂 Download PDFInfo
- Publication number
- CN111788182B CN111788182B CN201980012827.5A CN201980012827A CN111788182B CN 111788182 B CN111788182 B CN 111788182B CN 201980012827 A CN201980012827 A CN 201980012827A CN 111788182 B CN111788182 B CN 111788182B
- Authority
- CN
- China
- Prior art keywords
- azabicyclo
- pyridazin
- amine
- hexane
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862625656P | 2018-02-02 | 2018-02-02 | |
| US62/625,656 | 2018-02-02 | ||
| PCT/US2019/016300 WO2019152809A1 (en) | 2018-02-02 | 2019-02-01 | Antagonists of the muscarinic acetylcholine receptor m4 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111788182A CN111788182A (zh) | 2020-10-16 |
| CN111788182B true CN111788182B (zh) | 2023-09-26 |
Family
ID=67480022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980012827.5A Expired - Fee Related CN111788182B (zh) | 2018-02-02 | 2019-02-01 | 毒蕈碱性乙酰胆碱受体m4的拮抗剂 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11414406B2 (https=) |
| EP (1) | EP3746421B1 (https=) |
| JP (1) | JP7352294B2 (https=) |
| KR (1) | KR20200116945A (https=) |
| CN (1) | CN111788182B (https=) |
| AU (1) | AU2019216492A1 (https=) |
| CA (1) | CA3090130A1 (https=) |
| IL (1) | IL276411B2 (https=) |
| WO (1) | WO2019152809A1 (https=) |
| ZA (1) | ZA202004638B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018300980A1 (en) | 2017-07-12 | 2020-01-02 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| IL273924B2 (en) | 2017-10-20 | 2024-07-01 | Univ Vanderbilt | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2019126731A1 (en) | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| CA3141826A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CA3142351A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| CA3155864A1 (en) * | 2019-10-04 | 2021-04-08 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| MX2022010634A (es) * | 2020-02-28 | 2023-01-19 | Remix Therapeutics Inc | Derivados de piridazina para modular el empalme de acidos nucleicos. |
| WO2022111500A1 (en) | 2020-11-26 | 2022-06-02 | Rezubio Pharmaceuticals Co., Ltd | Anticholinergic agents |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004056811A1 (en) * | 2002-12-23 | 2004-07-08 | Ranbaxy Laboratories Limited | Flavaxate derivatives as muscarinic receptor antagonists |
| WO2006035282A2 (en) * | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| WO2007007281A2 (en) * | 2005-07-11 | 2007-01-18 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| CN101268071A (zh) * | 2005-10-21 | 2008-09-17 | 诺瓦提斯公司 | 治疗精神病和神经退行性疾病的新1-氮杂-双环烷基衍生物 |
| CN106459039A (zh) * | 2014-05-23 | 2017-02-22 | 豪夫迈·罗氏有限公司 | 为jak抑制剂的5‑氯‑2‑二氟甲氧基苯基吡唑并嘧啶化合物 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2676444B1 (fr) * | 1991-05-16 | 1995-03-10 | Sanofi Elf | Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant. |
| US7576074B2 (en) | 2002-07-15 | 2009-08-18 | Rice Kenneth D | Receptor-type kinase modulators and methods of use |
| US20040044029A1 (en) | 2002-08-14 | 2004-03-04 | Dart Michael J. | Azabicyclic compounds are central nervous system active agents |
| EP1618091A1 (en) | 2003-04-09 | 2006-01-25 | Ranbaxy Laboratories, Ltd. | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| DE102004039789A1 (de) | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2006035280A1 (en) | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| WO2008065500A2 (en) | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
| CA2672373C (en) * | 2006-12-19 | 2011-08-30 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| CN101230058A (zh) | 2007-01-23 | 2008-07-30 | 上海恒瑞医药有限公司 | 双环氮杂烷类衍生物、其制备方法及其在医药上的用途 |
| CN103102352B (zh) | 2011-11-15 | 2015-08-12 | 山东亨利医药科技有限责任公司 | 酪氨酸激酶抑制剂吲哚满酮衍生物 |
| AU2014224975B2 (en) | 2013-03-05 | 2017-09-14 | Merck Patent Gmbh | Triazolo(4,5-d)pyrimidine derivatives for the treatment of diseases such as cancer |
| EP2970200A1 (en) | 2013-03-13 | 2016-01-20 | Abbvie Inc. | Pyridine cdk9 kinase inhibitors |
| DK3126330T3 (en) | 2014-04-04 | 2019-04-23 | Pfizer | BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS |
| JO3579B1 (ar) | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
| BR112018008630A2 (pt) | 2015-11-06 | 2018-10-30 | Neurocrine Biosciences Inc | derivados de n-[2-(1-benzilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazina-1-carboxamida, seus usos, composição farmacêutica |
| IL294124B2 (en) | 2015-12-10 | 2024-02-01 | Ptc Therapeutics Inc | Methods for treating huntington's disease |
| EP3416639B1 (en) | 2016-02-16 | 2022-06-08 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| US20170355708A1 (en) | 2016-06-09 | 2017-12-14 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| JP2020530451A (ja) * | 2017-08-08 | 2020-10-22 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| AU2018352828A1 (en) * | 2017-10-17 | 2020-04-23 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| IL273924B2 (en) | 2017-10-20 | 2024-07-01 | Univ Vanderbilt | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2019089676A1 (en) | 2017-10-31 | 2019-05-09 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2019126559A1 (en) * | 2017-12-20 | 2019-06-27 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
-
2019
- 2019-02-01 IL IL276411A patent/IL276411B2/en unknown
- 2019-02-01 CN CN201980012827.5A patent/CN111788182B/zh not_active Expired - Fee Related
- 2019-02-01 US US16/966,306 patent/US11414406B2/en active Active
- 2019-02-01 JP JP2020541908A patent/JP7352294B2/ja active Active
- 2019-02-01 CA CA3090130A patent/CA3090130A1/en active Pending
- 2019-02-01 AU AU2019216492A patent/AU2019216492A1/en not_active Abandoned
- 2019-02-01 WO PCT/US2019/016300 patent/WO2019152809A1/en not_active Ceased
- 2019-02-01 KR KR1020207023725A patent/KR20200116945A/ko not_active Ceased
- 2019-02-01 EP EP19747509.8A patent/EP3746421B1/en active Active
-
2020
- 2020-07-27 ZA ZA2020/04638A patent/ZA202004638B/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004056811A1 (en) * | 2002-12-23 | 2004-07-08 | Ranbaxy Laboratories Limited | Flavaxate derivatives as muscarinic receptor antagonists |
| WO2006035282A2 (en) * | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| WO2007007281A2 (en) * | 2005-07-11 | 2007-01-18 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| CN101268071A (zh) * | 2005-10-21 | 2008-09-17 | 诺瓦提斯公司 | 治疗精神病和神经退行性疾病的新1-氮杂-双环烷基衍生物 |
| CN106459039A (zh) * | 2014-05-23 | 2017-02-22 | 豪夫迈·罗氏有限公司 | 为jak抑制剂的5‑氯‑2‑二氟甲氧基苯基吡唑并嘧啶化合物 |
Non-Patent Citations (1)
| Title |
|---|
| RN：2164592-45-2，2152087-70-0，2148484-96-0，2029853-92-5，2028000-90-8，2025026-23-5，2024724-04-5，2001685-84-1，1995218-19-3;美国化学会;《STNEXT》;第1-5页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200116945A (ko) | 2020-10-13 |
| US11414406B2 (en) | 2022-08-16 |
| IL276411B1 (en) | 2023-12-01 |
| US20200369650A1 (en) | 2020-11-26 |
| ZA202004638B (en) | 2023-02-22 |
| IL276411A (en) | 2020-09-30 |
| CA3090130A1 (en) | 2019-08-08 |
| EP3746421A4 (en) | 2021-10-27 |
| JP7352294B2 (ja) | 2023-09-28 |
| EP3746421B1 (en) | 2023-11-29 |
| IL276411B2 (en) | 2024-04-01 |
| EP3746421A1 (en) | 2020-12-09 |
| AU2019216492A1 (en) | 2020-08-20 |
| WO2019152809A1 (en) | 2019-08-08 |
| CN111788182A (zh) | 2020-10-16 |
| JP2021513519A (ja) | 2021-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111788182B (zh) | 毒蕈碱性乙酰胆碱受体m4的拮抗剂 | |
| CN111491920B (zh) | 毒蕈碱性乙酰胆碱受体m4的拮抗剂 | |
| US11352344B2 (en) | Antagonists of the muscarinic acetylcholine receptor M4 | |
| US11325896B2 (en) | Antagonists of the muscarinic acetylcholine receptor M4 | |
| US11225484B2 (en) | Substituted octahydropyrrolo[3,4-b]pyrroles as antagonists of the muscarinic acetylcholine receptor M4 | |
| EP3697781B1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| CN110891569A (zh) | 毒蕈碱性乙酰胆碱受体m4的拮抗剂 | |
| US20230122344A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| JP7099725B2 (ja) | ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子 | |
| US20240010640A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| US12516067B2 (en) | Antagonists of the muscarinic acetylcholine receptor M4 | |
| CN111406058A (zh) | 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20230926 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |